Show simple item record

dc.contributor.authorMarín-Mayor, Marta
dc.contributor.authorLópez-Muñoz, F.
dc.contributor.authorRubio, G.
dc.date.accessioned2018-06-27T12:00:59Z
dc.date.available2018-06-27T12:00:59Z
dc.date.issued2014-09-30
dc.identifier.citationMarín-Mayor M, López-Muñoz F, Rubio G (2014) Anticonvulsant Agents for the Management of Benzodiazepine Dependence. J Addict Addictv Disord 1: 003.es
dc.identifier.issn2578-7276
dc.identifier.urihttp://hdl.handle.net/20.500.12020/772
dc.description.abstractIntroduction Chronic use of Benzodiazepines (BZDs) can lead to tolerance and dependence, as indicated by a BZD Withdrawal Syndrome (BWS). In general, it is preferred a gradual than an abrupt tapering of BZDs as a first step in the treatment of BZD Dependence (BD). In addition, a great variety of agents have been used as adjuvant medication for BD. Recently, research has focused in the use of Anticonvulsant (AC) drugs. The aim of this article is to review the use of AC in the management of BWS and BD. Methods MEDLINE and the Cochrane were searched, selecting studies from 1980 until 2014, in which a pharmacological intervention with classic and new AC was made for discontinuing long-term BZD use. Results In regard to classic AC, there were identified 10 studies related to carbamazepine and 4 studies related to valproate. On one hand, whereas there is a great body of research involving carbamazepine and there is a consensus about its efficacy for discontinuing long-term BZD use, especially in terms of improving drug-free outcomes, there have been brought inconclusive results in regard to valproate. On the other hand, studies identified of the new AC are as follows: 2 for gabapentin, 2 for oxcarbazepine, 2 for pregabalin, 1 for tigabine and 2 for topiramate. With the exception of pregabalin, only small studies and cases report have been conducted for most of the new AC. Pregabalin has demonstrated to be effective in the treatment of BD and BWS, exerting its beneficial action by reducing the severity of withdrawal and anxiety symptoms. Conclusion To date, among AC agents, only carbamazepine and pregabalin can be considered as augmentation alternatives for the treatment of long-term BZD use. Further randomized, double-blind, placebo-controlled studies are necessary to increase the knowledge to support the use of AC for the treatment of BD and BWS.es
dc.language.isoenes
dc.publisherHeraldes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleAnticonvulsant Agents for the Management of Benzodiazepine Dependencees
dc.typearticlees
dc.issue.number3es
dc.journal.titleHSOA Journal of Addiction & Addictive Disorderses
dc.page.initial1es
dc.page.final10es
dc.rights.accessRightsopenAccesses
dc.subject.areaPsicologíaes
dc.subject.keywordAnticonvulsantses
dc.subject.keywordBenzodiazepineses
dc.subject.keywordDependencees
dc.subject.keywordWithdrawal syndromees
dc.subject.unesco61 Psicologíaes
dc.subject.unesco3201.05 Psicología Clínicaes
dc.subject.unesco3209 Farmacologíaes
dc.volume.number1es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional